Vol 3, No 1 (2017)
Review paper
Published online: 2017-04-19
Zastosowanie aceklofenaku w leczeniu chorób reumatycznych
Forum Reumatol 2017;3(1):29-34.
Abstract
Niesteroidowe leki przeciwzapalne nadal są szeroko stosowane i zajmują ważne miejsce w reumatologii. Niestety, wszystkie niesteroidowe leki przeciwzapalne mogą wywołać charakterystyczne działania niepożądane, dlatego poszukuje się leków o większym profilu bezpieczeństwa. Wiele badań klinicznych potwierdza dobrą skuteczność i bezpieczeństwo aceklofenaku w leczeniu chorób reumatycznych, co skłania do jego stosowania w codziennej praktyce klinicznej. W artykule przedstawiono krótką charakterystykę i zastosowanie aceklofenaku w reumatologii.
Keywords: niesteroidowe leki przeciwzapalneaceklofenakchoroby reumatyczne
References
- Kostowski W., Herman Z.: Farmakologia. Podstawy farmakoterapii. Wydawnictwo Lekarskie PZWL, Warszawa 2006
- Samborski W., Brzosko M.: Reumatologia praktyczna. Wydawnictwo Wolters Kluwert Polska SP. z o.o., Warszawa 2011
- Dooley M, Spencer CM, Dunn CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001; 61(9): 1351–1378.
- Schattenkirchner M, Milachowski KA. A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clin Rheumatol. 2003; 22(2): 127–135.
- Batlle-Gualda E, Román Ivorra J, Martín-Mola E, et al. Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6-week randomized controlled trial. Osteoarthritis Cartilage. 2007; 15(8): 900–908.
- Kornasoff D, Frerick H, Bowdler J, et al. Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. Clin Rheumatol. 1997; 16(1): 32–38.
- Martín-Mola E, Gijón-Baños J, Ansoleaga JJ. Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. Rheumatol Int. 1995; 15(3): 111–116.
- Pasero G, Marcolongo R, Serni U, et al. A multi-centre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis. Curr Med Res Opin. 1995; 13(6): 305–315.
- Batlle-Gualda E, Figueroa M, Ivorra J, et al. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. J Rheumatol. 1996; 23(7): 1200–1206.
- Frölich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci. 1997; 18(1): 30–34.
- Patrignani P, Panara MR, Sciulli MG, et al. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol. 1997; 48(4): 623–631.
- Bort R, Ponsoda X, Carrasco E, et al. Metabolism of aceclofenac in humans. Drug Metab Dispos. 1996; 24(8): 834–841.
- Henrotin Y, de Leval X, Mathy-Hartet M, et al. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res. 2001; 50(8): 391–399.
- Maneiro E, López-Armada MJ, Fernández-Sueiro JL, et al. Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J Rheumatol. 2001; 28(12): 2692–2699.
- Yamazaki R, Kawai S, Mizushima Y, et al. A major metabolite of aceclofenac, 4'-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin-1/proMMP-3 by human rheumatoid synovial cells. Inflamm Res. 2000; 49(3): 133–138.
- Akimoto H, Yamazaki R, Hashimoto S, et al. 4'-Hydroxy aceclofenac suppresses the interleukin-1-induced production of promatrix metalloproteinases and release of sulfated-glycosaminoglycans from rabbit articular chondrocytes. Eur J Pharmacol. 2000; 401(3): 429–436.
- Blot L, Marcelis A, Devogelaer JP, et al. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol. 2000; 131(7): 1413–1421.
- MacDonald TM. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology. 2000; 39(suppl 2): 13–20.
- Nagai J, Uesawa Y, Shimamura R, et al. Characterization of the Adverse Effects Induced by Acetaminophen and Non-steroidal Anti-Inflammatory Drugs based on the Analysis of the Japanese Adverse Drug Event Report Database. Clin J Pain. 2016 [Epub ahead of print].
- Bjorkman DJ. One hundred years of NSAID gastropathy: are coxibs the answer? Rev Gastroenterol Disord. 2001; 1(3): 121–127.
- Arfè A, Scotti L, Varas-Lorenzo C, et al. Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016; 354: i4857.
- Międzyborski R. Kierunki poszukiwań i zastosowanie niesteroidowych leków przeciwzapalnych. Postepy Hig Med Dosw. 2004; 58: 438–448.
- Pareek A, Chandanwale AS, Oak J, et al. Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac - an Indian experience. Curr Med Res Opin. 2006; 22(5): 977–988.
- Lapeyre-Mestre M, Grolleau S, Montastruc JL, et al. Association Française des Centres Régionaux de Pharmacovigilance (CRPV). Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002-2006. Fundam Clin Pharmacol. 2013; 27(2): 223–230.
- Laporte JR, Ibáñez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004; 27(6): 411–420.
- Castellsague J, Riera-Guardia N, Calingaert B, et al. Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012; 35(12): 1127–1146.
- Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004; 5(6): 1347–1357.
- Hawkey CJ, Ell C, Simon B, et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol. 2008; 6(5): 536–544.
- Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005; 128(5): 1172–1178.
- Goldstein JL, Eisen GM, Lewis B, et al. Investigators. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005; 3(2): 133–141.
